Secondary hyperparathyroidism (SHPT) is a challenge frequently encountered in the
management of patients with chronic kidney disease (CKD). Downregulation of the …

Hypertension is a frequent condition encountered during kidney disease development and a
leading cause in its progression. Hallmark factors contributing to hypertension constitute a …

Introduction: Chronic kidney disease as a public health problem. Chronic kidney disease is
a worldwide public health problem. In the United States, there is a rising incidence and …

Masafumi Fukagawa, 1 Keitaro Yokoyama, 1 Fumihiko Koiwa, 1 Masatomo Taniguchi, 1
Tetsuo Shoji, 1 Junichiro James Kazama, 1 Hirotaka Komaba, 1 Ryoichi Ando, 1 Takatoshi …

Background Treatment of secondary hyperparathyroidism with vitamin D and calcium in
patients receiving dialysis is often complicated by hypercalcemia and hyperphosphatemia …

Patients with ESRD commonly experience secondary hyperparathyroidism, a condition
primarily managed with activated injectable vitamin D. The biologic effects of vitamin D …

In the course of chronic kidney disease (CKD), alterations in the bone-vascular axis
augment the risk of bone loss, fractures, vascular and soft tissue calcification, left ventricular …

It is unknown why sustained elevation of parathyroid hormone (PTH) stimulates bone
resorption, whereas intermittent administration stimulates bone formation. We show in mice …

The vitamin D endocrine system is critical for the proper development and maintenance of
mineral ion homeostasis and skeletal integrity. Beyond these classical roles, recent …

Bone loss and increased fractures are common complications in chronic kidney disease.
Because Wnt pathway activation is essential for normal bone mineralization, we assessed …